Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Cassinello J, Climent MA, González del Alba A, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol 2014;16:1060–6.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
   PubMed Web of Science ®Google Scholar
• Oudard S, Angelergues A. Prostate cancer: cabazitaxel–the taxane of choice in the new mCRPC landscape? Nat Rev Urol 2014;11:370–2.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.
   PubMed Web of Science ®Google Scholar
• Pezaro CJ, Omlin AG, Altavilla A, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014;66:459–65.
   PubMed Web of Science ®Google Scholar
• Reddy LH, Bazile D. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. Adv Drug Deliv Rev 2014;71:34–57.
   PubMed Web of Science ®Google Scholar
• Bensaid F, Thillaye du Boullay O, Amgoune A, et al. shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core-corona nanoparticles. Biomacromolecules 2013;14:1189–98.
   PubMed Web of Science ®Google Scholar
• Diou O, Greco S, Beltran T, et al. A method to quantify the affinity of cabazitaxel for PLA-PEG nanoparticles and investigate the influence of the nano-assembly structure on the drug/particle association. Pharm Res 2015;32:3188–200.
   PubMed Web of Science ®Google Scholar
• Shao Y, Zhang C, Yao Q, et al. Improving cabazitaxel chemical stability in parenteral lipid emulsions using cholesterol. Eur J Pharm Sci 2014;52:1–11.
   PubMed Web of Science ®Google Scholar
• Song Y, Tian Q, Huang Z, et al. Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. Int J Nanomedicine 2014;9:2307–17.
   PubMed Web of Science ®Google Scholar
• Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013;65:1667–85.
   PubMed Web of Science ®Google Scholar
• Adesina SK, Wight SA, Akala EO. Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design. Drug Dev Ind Pharm 2014;40:1547–56.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Zhang X, et al. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv 2015. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1069423.
   Web of Science ®Google Scholar
• Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine 2013;9:474–91.
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Reddy Karri VV, et al. Lipid-based nanocarriers for breast cancer treatment - comprehensive review. Drug Deliv 2015. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1092183.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Khan S, Maher DM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 2014;35:8635–48.
   PubMed Web of Science ®Google Scholar
• Martin AL, Hickey JL, Ablack AL, et al. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanopart Res 2009;12:1599–608.
   PubMed Web of Science ®Google Scholar
• Accardo A, Salsano G, Morisco A, et al. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine 2012;7:2007–17.
   PubMed Web of Science ®Google Scholar
• Accardo A, Mansi R, Salzano G, et al. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells. J Drug Target 2012. [Epub ahead of print]. DOI: 10.3109/1061186X.2012.741138.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Singh MK, et al. Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer. Nanomedicine (Lond) 2015;10:2847–59.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Shrivastava S, et al. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces 2014;117:166–73.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun X, Wang K, et al. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Drug Deliv 2015. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1049721.
   Google Scholar
• Lalani J, Rathi M, Lalan M, Misra A. Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Dev Ind Pharm 2013;39:854–64.
   PubMed Web of Science ®Google Scholar
• Khan S, Baboota S, Ali J, et al. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. Drug Dev Ind Pharm 2016;42:209–20.
   PubMed Web of Science ®Google Scholar
• Heidari Z, Sariri R, Salouti M. Gold nanorods-bombesin conjugate as a potential targeted imaging agent for detection of breast cancer. J Photochem Photobiol B Biol 2014;130:40–6.
   PubMed Web of Science ®Google Scholar
• Golla K, Reddy PS, Bhaskar C, Kondapi AK. Biocompatibility, absorption and safety of protein nanoparticle-based delivery of doxorubicin through oral administration in rats. Drug Deliv 2013;20:156–67.
   PubMed Web of Science ®Google Scholar
• Zhuang B, Du L, Xu H, et al. Self-assembled Micelle Loading Cabazitaxel for therapy of Lung Cancer. Int J Pharm 2016;499:146–55.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Gao Y, Wu C, et al. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets. Drug Dev Ind Pharm 2016;42:199–208.
   PubMed Web of Science ®Google Scholar
• Valizadeh H, Ghanbarzadeh S, Zakeri-Milani P. Fusogenic liposomal formulation of sirolimus: improvement of drug anti-proliferative effect on human T-cells. Drug Dev Ind Pharm 2015;41:1558–65.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li H, Guan S. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Dev Ind Pharm 2015;41:177–82.
   PubMed Web of Science ®Google Scholar
• Md S, Ali M, Baboota S, et al. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 2014;40:278–87.
   PubMed Web of Science ®Google Scholar
• Ukawala M, Rajyaguru T, Chaudhari K, et al. Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles. Drug Deliv 2012;19:155–67.
   PubMed Web of Science ®Google Scholar
• Jindal AB, Devarajan PV. Asymmetric lipid-polymer particles (LIPOMER) by modified nanoprecipitation: role of non-solvent composition. Int J Pharm 2015;489:246–51.
   PubMed Web of Science ®Google Scholar
• Mokhtar Ibrahim M, Tawfique SA, Mahdy MM. Liposomal diltiazem HCl as ocular drug delivery system for glaucoma. Drug Dev Ind Pharm 2014;40:765–73.
   PubMed Web of Science ®Google Scholar
• Lin A, Chen J, Liu Y, et al. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm 2009;35:1348–55.
   PubMed Web of Science ®Google Scholar
• Shalaby KS, Soliman ME, Casettari L, et al. Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomedicine 2014;9:4953–64.
   PubMed Web of Science ®Google Scholar
• Rayaprolu BM, Strom JG. Design and evaluation of D-α tocopheryl polyethylene glycol 1000 succinate emulsified poly-ε-caprolactone nanoparticles for protein/peptide drug delivery. Drug Dev Ind Pharm 2013;39:1046–52.
   PubMed Web of Science ®Google Scholar
• Čerpnjak K, Zvonar A, Vrečer F, Gašperlin M. Development of a solid self-microemulsifying drug delivery system (SMEDDS) for solubility enhancement of naproxen. Drug Dev Ind Pharm 2015;41:1548–57.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Kulhari DP, Singh MK, Sistla R. Colloidal stability and physicochemical characterization of bombesin conjugated biodegradable nanoparticles. Colloids Surfaces A 2014;443:459–66.
   Web of Science ®Google Scholar
• Mandal B, Mittal NK, Balabathula P, et al. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Eur J Pharm Sci 2016;81:162–71.
   PubMed Web of Science ®Google Scholar
• Rose F, Wern JE, Ingvarsson PT, et al. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release 2015;210:48–57.
   PubMed Web of Science ®Google Scholar
• Xia B, Liu X, Zhou Q, et al. Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. Drug Dev Ind Pharm 2013;39:845–53.
   PubMed Web of Science ®Google Scholar
• Biswas S, Torchilin VP. Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev 2014;66:26–41.
   PubMed Web of Science ®Google Scholar
• Shi K, Zhou J, Zhang Q, et al. Arginine-Glycine-Aspartic Acid-Modified Lipid-Polymer Hybrid Nanoparticles for Docetaxel Delivery in Glioblastoma Multiforme. J Biomed Nanotechnol 2015;11:382–91.
   PubMed Web of Science ®Google Scholar